Table 1.
Baseline characteristics of patients enrolled in the PSO-BIO-REAL study
| Characteristic | Biologic-naïvea(N = 509) | Biologic-experiencedb (N = 337) | Index biologicc | Overall(N = 846) | |||
|---|---|---|---|---|---|---|---|
| Adalimumab (n = 343) | Etanercept (n = 143) | Ustekinumab (n = 256) | Secukinumab (n = 76) | ||||
| Age, years, mean (SD) | 45.7 (14.0) | 50.0 (12.9) | 46.4 (14.0) | 49.4 (14.6) | 46.0 (13.3) | 50.8 (11.5) | 47.4 (13.8) |
| Male, n (%) | 321 (63.1) | 214 (63.5) | 207 (60.3) | 98 (68.5) | 158 (61.7) | 52 (68.4) | 535 (63.2) |
| White, n (%) | 473 (92.9) | 308 (91.4) | 312 (91.0) | 139 (97.2) | 232 (90.6) | 70 (92.1) | 781 (92.3) |
| BMI, kg/m2, mean (SD) (n = 830) | 28.8 (6.8) | 30.3 (6.7) | 29.0 (6.7) | 29.0 (6.7) | 29.2 (6.8) | 31.0 (5.7) | 29.4 (6.8) |
| Duration of psoriasis, years, mean (SD) | 17.1 (13.3) | 20.4 (12.8) | 17.8 (12.9) | 19.7 (14.7) | 18.2 (13.1) | 20.3 (12.7) | 18.4 (13.2) |
| Psoriatic arthritis, yes, n (%) | 119 (23.4) | 119 (35.3) | 96 (28.0) | 46 (32.2) | 67 (26.2) | 22 (28.9) | 238 (28.1) |
| Prior biologic use, n (%) | 2 (0.4) | 337 (100.0) | 88 (25.7) | 32 (22.4) | 154 (60.2) | 49 (64.5) | 339 (40.1) |
| PASI, mean (SD) | 14.38 (8.5) | 14.18 (10.5) | 13.9 (8.5) | 14.0 (8.4) | 13.8 (9.4) | 16.6 (12.1) | 14.3 (9.3) |
| PSI, mean (SD) | 17.4 (7.7) | 17.1 (7.8) | 17.0 (7.6) | 16.5 (7.6) | 17.5 (7.6) | 18.4 (7.99) | 17.3 (7.8) |
| DLQI, mean (SD) | 12.9 (7.6) | 11.6 (7.7) | 12.1 (7.3) | 11.9 (7.4) | 12.6 (7.8) | 13.8 (8.4) | 12.4 (7.6) |
BMI Body mass index, DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index, PSI Psoriasis Symptom Inventory, SD standard deviation
aSubjects who were not exposed to biologic treatment prior to study enrolment
bSubjects who received biologic treatment prior to study enrolment but switched to a different biologic at study entry
cTwo patients received certolizumab pegol and 26 patients received infliximab. Aggregated baseline characteristics for these patients have not been reported separately by index biologic because of low numbers